Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 11/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24988126 | 0.95 | MAPT (0.46) | SPHK2SPHK1MAPTTSHRNOTUM | |
| SCHEMBL25914443 | 0.95 | MAPT (0.46) | SPHK2SPHK1MAPTTSHRNOTUM | |
| SCHEMBL25914367 | 0.87 | TSHR (0.50) | SPHK2SPHK1MAPTTSHRNOTUM | |
| SCHEMBL25914441 | 0.87 | MAPT (0.46) | MAPTTSHRNOTUMCYP1A2CYP3A4 | |
| SCHEMBL24988632 | 0.86 | KIT (0.52) | SPHK2SPHK1NPC1RAB9AKIT | |
| SCHEMBL24988518 | 0.86 | MAPT (0.43) | SPHK2SPHK1MAPTTSHRNOTUM | |
| SCHEMBL24987968 | 0.83 | SMN1; SMN2 (0.46) | SPHK2SPHK1MAPTTSHRNOTUM | |
| SCHEMBL24987982 | 0.82 | TSHR (0.48) | MAPTTSHRNOTUMCYP1A2CYP2D6 | |
| SCHEMBL24989004 | 0.82 | TSHR (0.48) | MAPTTSHRNOTUMCYP1A2CYP2D6 | |
| SCHEMBL31682248 | 0.81 | SPHK2 (0.43) | SPHK2SPHK1NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624011-B2 | Oxadiazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-05-12 | — | — | US | claimed |
| EP-4122923-B1 | OXADIAZOLE DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2025-09-10 | — | — | EP | claimed |
| US-20230265061-A1 | OXADIAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-24 | — | — | US | claimed |
| EP-4122923-A1 | OXADIAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-25 | — | — | EP | claimed |
| CN-115515943-A | Oxadiazole derivatives | 住友制药株式会社 | 2022-12-23 | — | — | CN | claimed |
| US-12624011-B2 | Oxadiazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-05-12 | — | — | US | disclosed |
| CN-115515943-B | Oxadiazole derivatives | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| US-20230265061-A1 | OXADIAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265061-A1 | OXADIAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265061-A1 | OXADIAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11718592-B2 | Oxadiazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-08 | — | — | US | disclosed |
| US-11718592-B2 | Oxadiazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-08 | — | — | US | disclosed |
| US-11718592-B2 | Oxadiazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-08 | — | — | US | disclosed |
| US-20230092498-A1 | OXADIAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-4122923-A1 | OXADIAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-25 | — | — | EP | disclosed |
| CN-115515943-A | Oxadiazole derivatives | 住友制药株式会社 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092498-A1 | OXADIAZOLE DERIVATIVE | OXA1L, SCN1A, CACNA1A | SPHK2 2837/4885SPHK1 2721/4885MAPT 1620/4885 |
| US-11718592-B2 | Oxadiazole derivative | OXA1L, SCN1A, CACNA1A | SPHK2 2837/4885SPHK1 2721/4885MAPT 1620/4885 |
| US-20230265061-A1 | OXADIAZOLE DERIVATIVE | OXA1L, SCN1A, CACNA1A | SPHK2 2837/4885SPHK1 2721/4885MAPT 1620/4885 |
| US-12624011-B2 | Oxadiazole derivative | HSD3B1, CBR3, CBR1 | SPHK2 1953/4885SPHK1 1792/4885MAPT 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.